Patents by Inventor Julio A. Munoz

Julio A. Munoz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroxybenzoate salts of metanicotine compounds
    Patent number: 8778978
    Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: July 15, 2014
    Assignee: Targacept, Inc.
    Inventors: Julio A. Munoz, John Genus, James R. Moore
  • PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S, 3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE
    Publication number: 20140163065
    Abstract: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).
    Type: Application
    Filed: May 14, 2013
    Publication date: June 12, 2014
    Applicant: TARGACEPT, INC.
    Inventors: Merouane Bencherif, Nikolai Fedorov, Terry Hauser, Kristen Jordan, Sharon Rae Letchworth, Anatoly Mazurov, Julio A. Munoz, Jason Speake, Daniel Yohannes
  • SYNTHESIS AND NOVEL SALT FORMS OF (R)-3-((E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE
    Publication number: 20140107163
    Abstract: The present invention relates to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions.
    Type: Application
    Filed: December 16, 2013
    Publication date: April 17, 2014
    Applicant: Targecept, Inc.
    Inventors: Srinvasa Rao Akireddy, Scott R. Breining, Timothy J. Cuthbertson, Gary Maurice Dull, Gregory J. Gatto, John Genus, Phillip S. Hammond, Joseph Pike Mitchener, JR., Julio A. Munoz, Pieter Albert Otten, Daniel Yohannes, Nikolai Fedorov
  • SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE
    Publication number: 20140066460
    Abstract: The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.
    Type: Application
    Filed: November 7, 2013
    Publication date: March 6, 2014
    Applicant: Targacept, Inc.
    Inventors: Srinivasa Rao Akireddy, Balwinder Singh Bhatti, Timothy J. Cuthbertson, Gary Maurice Dull, Craig Harrison Miller, Joseph Pike Mitchener, Julio A. Munoz, Pieter Albert Otten
  • HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS
    Publication number: 20140039014
    Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
    Type: Application
    Filed: October 3, 2013
    Publication date: February 6, 2014
    Applicant: Targacept, Inc.
    Inventors: Julio A. Munoz, John Genus, James R. Moore
  • (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZYOFURN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF
    Publication number: 20140024673
    Abstract: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.
    Type: Application
    Filed: July 22, 2013
    Publication date: January 23, 2014
    Applicant: Targacept,Inc.
    Inventors: Merouane Bencherif, Lisa Benson, Gary Maurice Dull, Nikolai Federov, Gregory J. Gatto, Kristen G. Jordan, Anatoly A. Mazurov, Lan Miao, Julio A. Munoz, Inigo Pfeiffer, Sondra Pfeiffer, Teresa Phillips
  • Synthesis and novel salt forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine
    Patent number: 8633227
    Abstract: The present invention relates to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: January 21, 2014
    Assignee: Targacept, Inc.
    Inventors: Srinivasa Rao Akireddy, Scott R. Breining, Timothy J. Cuthbertson, Gary Maurice Dull, Gregory J. Gatto, John Genus, Philip S. Hammond, Joesph Pike Mitchener, Jr., Julio A. Munoz, Pieter Albert Otten, Daniel Yohannes, Nikolai Fedorov
  • Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3YLVINYL)pyrimidine
    Patent number: 8604191
    Abstract: The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-yl)pyrimidine, novel salt forms, and novel polymorphic forms of these salts.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: December 10, 2013
    Assignee: Targacept, Inc.
    Inventors: Srinivasa Rao Akireddy, Balwinder Singh Bhatti, Timothy J. Cuthbertson, Gary Maurice Dull, Craig Harrison Miller, Joseph Pike Mitchener, Jr., Julio A. Munoz, Pieter Albert Otten
  • NOVEL POLYMORPH FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-ISOPROPOXYPYRIDIN)YL]-4-PENTEN-2-AMINE
    Publication number: 20130310425
    Abstract: Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, and methods for their preparation, pharmaceutical composition containing said polymorph(s) and use, are disclosed. The polymorphs can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.
    Type: Application
    Filed: May 14, 2013
    Publication date: November 21, 2013
    Applicant: Targacept, Inc.
    Inventors: Gary Maurice Dull, Julio A. Munoz
  • Hydroxybenzoate salts of metanicotine compounds
    Patent number: 8580826
    Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: November 12, 2013
    Assignee: Targacept, Inc.
    Inventors: Julio A. Munoz, John Genus, James R. Moore
  • (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofurn-2-carboxamide, novel salt forms, and methods of use thereof
    Patent number: 8541446
    Abstract: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: September 24, 2013
    Assignee: Targacept, Inc.
    Inventors: Merouane Bencherif, Lisa Benson, Gary Maurice Dull, Nikolai Fedorov, Gregory J. Gatto, Kristen G. Jordan, Anatoly A. Mazurov, Lan Miao, Julio A. Munoz, Inigo Pfeiffer, Sondra Pfeiffer, Teresa Phillips
  • Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide
    Patent number: 8476296
    Abstract: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).
    Type: Grant
    Filed: January 25, 2010
    Date of Patent: July 2, 2013
    Assignee: Targacept, Inc.
    Inventors: Merouane Bencherif, Nikolai Fedorov, Terry Hauser, Kristen Jordan, Sharon Rae Letchworth, Anatoly Mazurov, Julio A. Munoz, Jason Speake, Daniel Yohannes
  • Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropdxypyridin)yl]-4-penten-2-amine
    Patent number: 8461344
    Abstract: Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, and methods for their preparation, pharmaceutical composition containing said polymorph(s) and use, are disclosed. The polymorphs can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: June 11, 2013
    Assignee: Targacept, Inc.
    Inventors: Gary M. Dull, Julio A. Munoz
  • FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
    Publication number: 20120053168
    Abstract: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).
    Type: Application
    Filed: February 16, 2010
    Publication date: March 1, 2012
    Applicant: Targacept, Inc.
    Inventors: Balwinder Singh Bhatti, Timothy J. Cuthbertson, Anatoly Mazurov, Joseph Pike Mitchener, Julio A. Munoz, Srinivasa V. Murthy, Yunde Xiao, Daniel Yohannes
  • HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS
    Publication number: 20120041033
    Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
    Type: Application
    Filed: October 26, 2011
    Publication date: February 16, 2012
    Inventors: Julio A. Munoz, John Genus, James R. Moore
  • Synthesis and Novel Salt Forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine
    Publication number: 20120015983
    Abstract: The present invention relates to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions.
    Type: Application
    Filed: November 30, 2009
    Publication date: January 19, 2012
    Applicant: Targacept, Inc.
    Inventors: Srinivasa Rao Akireddy, Scott R. Breining, Timothy J. Cuthbertson, Gary Maurice Dull, Gregory J. Gatto, John Genus, Philip S. Hammond, Joseph Pike Mitchener, Julio A. Munoz, Pieter Albert Otten, Daniel Yohannes, Nikolai Fedorov
  • SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE
    Publication number: 20110281895
    Abstract: The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-yl)pyrimidine, novel salt forms, and novel polymorphic forms of these salts.
    Type: Application
    Filed: November 30, 2009
    Publication date: November 17, 2011
    Applicant: TARGACEPT, INC.
    Inventors: Srinivasa Rao Akireddy, Balwinder Singh Bhatti, Timothy J. Cuthbertson, Gary Maurice Dull, Craig Harrison Miller, Joseph Pike Mitchener, JR., Julio A. Munoz, Pieter Albert Otten
  • Hydroxybenzoate salts of metanicotine compounds
    Patent number: 8053451
    Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
    Type: Grant
    Filed: November 4, 2008
    Date of Patent: November 8, 2011
    Assignee: Targacept, Inc.
    Inventors: Julio A. Munoz, John Genus, James R. Moore
  • PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE
    Publication number: 20110257224
    Abstract: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetyl-choline receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).
    Type: Application
    Filed: January 25, 2010
    Publication date: October 20, 2011
    Applicant: Targacept, Inc
    Inventors: Merouane Bencherif, Nikolai Fedorov, Terry Hauser, Kristen Jordan, Sharon Rae Letchworth, Anatoly Mazurov, Julio A. Munoz, Jason Speake, Daniel Yohannes
  • Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
    Patent number: 8017785
    Abstract: Phosphoric acid, edisylic acid (1,2-ethanedisulfonic acid), citric acid, orotic acid (uracil-6-carboxylic acid), R-mandelic acid, sulfuric acid, 1,5-naphthalenedisulfonic acid, D-aspartic acid, and lysine monohydrochloride salts of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine, and methods for their preparation, pharmaceutical compositions comprising said salts, and use, are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: September 13, 2011
    Assignees: AstraZeneca AB, Targacept, Inc.
    Inventors: Caroline Ericsson, Martin Bohlin, Tesfai Sebhatu, Gary M. Dull, Julio A. Munoz, Craig H. Miller